Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501
Latest Information Update: 07 Apr 2025
At a glance
- Drugs AMXT 1501 (Primary) ; Eflornithine (Primary)
- Indications Glioma
- Focus First in man; Therapeutic Use
Most Recent Events
- 29 Aug 2023 Planned End Date changed from 15 Jan 2026 to 15 Sep 2027.
- 29 Aug 2023 Planned primary completion date changed from 15 Jan 2025 to 15 Jan 2027.
- 06 Jun 2023 Study design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.